CEO Eric Lefkofsky said the purchase of Ambry Genetics will expand Tempus’ testing portfolio and bring in a fast-growing ...

The last decade has seen a swell of biotech startups using AI to design proteins. These are seven companies to watch.

Scientists have provided new insights into muscle aging, identifying critical genes and mechanisms through the use of ...

Researchers at Stanford Medicine have developed an AI-based method to identify complex structural variants in the human ...

Researchers are warning that artificial intelligence tools gaining popularity in the fields of genetics and medicine can lead to flawed conclusions about the connection between genes and physical ...

With Ambry Genetics in tow, Eric Lefkofsky's biotech startup hopes to accelerate its drive toward turning a profit.

Aliso Viejo-based Ambrey Genetics Corp., Orange County’s third-largest medical diagnostics and testing company, has entered ...

DNA synthesis platform developer joins de novo designer in latest of three partnerships recently launched or advanced.

Tempus AI said it agreed to pay $375 million in cash and $225 million in shares to acquire genetic testing company Ambry Genetics. Ambry conducts hereditary cancer screening and currently serves as ...

Tempus announced that it has entered into an agreement to acquire Ambry Genetics, a leader in genetic testing. Under the terms of the ...

Accenture (NYSE: ACN) has invested, through Accenture Ventures, in 1910 Genetics (or “1910”), a biotechnology company advancing small and large molecule drug discovery with a multimodal AI ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we ...